New Jersey is currently home to 1661 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
NCT00823654
Recruiting
The purpose of this study is to see how the cancer treatment affects the ovaries. Cancer treatment can make it hard for a person to conceive a child in the future. It may also bring on early menopause. We will check blood levels of hormones that the ovaries produce. We will do this before, during, and after the cancer treatment. We will also ask the patient to fill out questionnaires about their menstrual cycle (periods) and information about your health and pregnancies. This may help us learn w... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
04/10/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Breast Cancer
Register for Updates
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491
Recruiting
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/09/2025
Locations: The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Register for Updates
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Jersey Shore University Medical Center/Meridian Hematology & Oncology, Neptune, New Jersey
Conditions: NSCLC
Register for Updates
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Metastatic Breast Cancer
Register for Updates
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
NCT05873205
Recruiting
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Blood Cancer, Refractory Immune Cytopenias
Register for Updates
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
NCT05831202
Recruiting
To establish the safety and effectiveness of the SEAL™ Saccular Endovascular Aneurysm Lattice system for the treatment of saccular intracranial aneurysms. The data from this study will be used to support a premarket approval (PMA) submission.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/09/2025
Locations: The Cooper Health System, Camden, New Jersey
Conditions: Intracranial Aneurysm
Register for Updates
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
NCT05787574
Recruiting
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Fun... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Center for Emotional Fitness Site, Cherry Hill, New Jersey
Conditions: Generalized Anxiety Disorder
Register for Updates
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Recruiting
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Hackensack Meridian John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Rutgers-New Jersey Medical School, Newark, New Jersey
Conditions: Alcohol Associated Hepatitis
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Atlantic Health System / Morristown Medical Center, Morristown, New Jersey
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Register for Updates
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264
Recruiting
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Oncology Clinical Research Referral Office, Hackensack, New Jersey
Conditions: Low Risk Myelodysplastic Syndromes
Register for Updates